TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo May 9, 2022 David J. Arthur Chief Executive Officer Salarius Pharmaceuticals, Inc. 2450 Holcombe Blvd., Suite X Houston, TX 77021 Re: Salarius Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 25, 2022 File No. 001-36812 Dear Mr. Arthur: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences